Search results
Results from the WOW.Com Content Network
Inflammatory myofibroblastic tumor was initially regarded as a benign tumor that most often developed in the lung and less commonly in almost any organ system or tissue. Over time, however, IMT cases occurred in which the tumor spread into local tissues, metastasized to distal tissues, recurred after treatment, or consisted of neoplastic cells ...
Desmoid-type fibromatosis, also termed desmoid tumor and aggressive fibromatosis [26] Lipofibromatosis, a mixture of lipofibromatosis tumors with different gene abnormalities; [27] these tumors differ from lipofibromatosis-like neural tumors which have not been classified as fibroblastic and myofibroblastic tumors. Giant cell fibroblastoma [28]
Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) might share several aspects of the XP. Likewise there might be some superimpositions between the XP and the plasma cell granuloma/histiocytoma-inflammatory myofibroblastic tumor complex. [18] [19] The XP might be an important stage of this complex.
NF may resemble and therefore be misdiagnosed as dermatofibrosarcoma protuberans, fibrosarcoma, malignant fibrous histiocytoma, spindle-cell melanoma, [27] leiomyosarcoma, [4] or inflammatory myofibroblastic tumor. [8] The diagnosis of NF and its variants depends on a combination of findings, no single one of which is definitive.
An inflammatory pseudotumor is a cell proliferation and inflammation involving spindle cells, which may occur in many parts of the body, and is of unknown case. [1] According to the WHO classification, three lesional patterns can be observed: Inflammatory myofibroblastic tumour, that can be associated with an ALK gene rearrangement
Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas. [1] As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of fibroblasts and smooth muscle cells) by Mentzel et al. in 1998. [2]
The World Health Organization in 2020 classified mammary type myofibroblastoma tumors and myofibroblastoma tumors (i.e. extramammary myofibroblastic tumors) as separate tumor forms within the category of fibroblastic and myofibroblastic tumors. [8] Mammary MFB likely represents less than 1% of all breast tumors. [9]
Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, [1] high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, [2] is characterized by the World Health Organization (WHO) as a rare, poorly differentiated neoplasm (i.e., an abnormal growth of cells that have an unclear identity and/or cell of origin). [3]